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IL-6 Modulates Alpha-Smooth Muscle Actin
Expression in Dermal Fibroblasts from
IL-6-Deficient Mice
Randle M. Gallucci1, Eric G. Lee1 and James J. Tomasek2
IL-6 deficient (IL-6KO) mice display significantly delayed cutaneous wound closure. Myofibroblasts are the
primary mediators of wound closure, and alpha-smooth muscle actin (a-SMA) is a marker of fibroblast
differentiation to the myofibroblast phenotype. Wounds from IL-6KO, and wild-type mice were collected up to
6 days following wounding. Expression of a-SMA mRNA was found to be increased in wounds of IL-6KO mice up
to 48 hours post wounding, but decreased below wild-type levels by 72 hours. Recombinant IL-6 treatment of
IL-6KO dermal fibroblasts showed an induction of a-SMA mRNA and protein peaking at 1 ng/ml cytokine, but
declining at higher concentrations. Actinomycin-D treatment of fibroblast cultures indicated that recombinant
mouse IL-6 (rmIL-6) induction of a-SMA mRNA appeared to be primarily transcriptionally regulated, and
extracellular signal-regulated kinase 1/2 kinase, but not signal transducers and activators of transcription 3 was
readily phosphorylated in rmIL-6 treated IL-6KO fibroblasts. A dose–response increase in the mRNA expression
of the IL-6R signaling inhibitor protein suppressors of cytokine signaling (SOCS) 3 was also noted in rmIL-6-
treated IL-6KO fibroblasts. These data indicate that a-SMA expression is dysregulated in IL-6KO mice. The
expression of a-SMA induced by rmIL-6 in fibroblasts from IL-6KO mice appears to be transcriptionally
modulated, dependent on JAK1 kinase, and possibly downregulated as a result of increased SOCS3 expression.
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INTRODUCTION
IL-6 is a pleiotropic cytokine that is involved in the growth
and differentiation of numerous cell types including those of
dermal and epidermal origin (Sehgal, 1990). In the skin, it is
produced primarily by epidermal keratinocytes, whereas
macrophages, Langerhans’ cells, and fibroblasts in the dermis
represent other sources of the cytokine (Paquet and Pierard,
1996). Increased levels of IL-6 have been associated with a
number of skin pathologies, such as psoriasis (Grossman
et al., 1989), scleroderma (Koch et al., 1993), and systemic
lupus erythematosus (Fugger et al., 1989). Overexpression of
IL-6 in the skin of normal rats induces epidermal proliferation
and inflammation (Sawamura et al., 1998), whereas trans-
genic mice overexpressing IL-6 display little more than a
thickened stratum corneum (Turksen et al., 1992). In contrast
to overexpressing transgenic animals, IL-6-deficient (IL-6KO)
mice display significantly delayed cutaneous wound healing
compared to wild-type control animals (Gallucci et al.,
2001b; Lin et al., 2003). Wounds from IL-6KO mice
displayed multiple defects including delayed re-epitheliali-
zation, greatly decreased granulation tissue, inhibited neo-
vascularization, and delayed wound closure.
In the United States, over 6 million individuals develop
chronic skin ulcers annually (Singer and Clark, 1999), and the
restoration or augmentation of cutaneous wound healing has
long been an elusive goal for health-care professionals.
Following trauma to the skin, these diverse cell types of the
dermis and epidermis must interact and cooperate in an
orderly sequence of events that, when simplified includes
coagulation, inflammation, formation of a provisional
collagen matrix (granulation tissue), re-epithelialization, and
remodeling (for a review see Bello and Phillips, 2000).
Wound closure is an important process in the proper healing
of skin. The contraction of wound tissue is primarily accom-
plished by so-called myofibroblasts, which form from normal
dermal fibroblasts (for a review see Tomasek et al., 2002).
During differentiation to the smooth muscle-like myofibroblast
phenotype, dermal fibroblasts begin to express contractile
proteins such as non-muscle myosin and a-smooth muscle
actin (a-SMA), and orient themselves horizontally in the dermis
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(Hinz et al., 2001). In this position, the cells can contract in the
granulation tissue to decrease the area of the wound.
Although it is known that wound closure is dependent on
myofibroblast activity, the process by which dermal fibroblasts
differentiate to this phenotype is not entirely understood. There
are indications that certain cytokines and growth factors may
be involved, such as platelet-derived growth factor (Martin,
1997), transforming growth factor (TGF)-b1 (Ronnov-Jessen
and Petersen, 1993; Vaughan et al., 2000), and inflammatory
cytokines such as tumor necrosis factor-a (Mews et al., 2002).
Herein, we describe the modulation of a-SMA expression
in dermal fibroblasts from IL-6KO mice by the inflammatory
cytokine, IL-6. We show not only that a-SMA is dysregulated
in IL-6KO mice, but also that recombinant mouse IL-6
(rmIL-6) can modulate a-SMA in primary fibroblast cultures.
Modulation in vitro is not merely upregulation of the protein,
but rather a variable regulation of expression where low
levels of IL-6 increase expression, and higher levels inhibit it.
These data may have important implications in the develop-
ment of treatments for chronic wounds, as well as for
pathologies associated with myofibroblast disregulation such
as Dupuytren’s disease, or contractures from burn injury.
RESULTS
Modulation of wound a-smooth muscle actin in IL-6KO mice
As stated in the Introduction, IL-6KO mice display significantly
decreased wound closure as compared to wild-type controls
(Gallucci et al., 2001b; Lin et al., 2003). As the myofibroblast is
primarily responsible for wound contraction, and a-SMA is a
marker for myofibroblast differentiation, mRNA expression of a-
SMA was measured in IL-6KO and wild-type control wounds.
Time course analysis of wound a-SMA mRNA by real-time PCR
analysis revealed that IL-6KO mice express significantly higher
(B9-fold) levels of a-SMA up to 24 hours post wounding
(Figure 1). However, 48 hours post-wounding a-SMA levels
were not significantly different between groups, and by 72 hours
IL-6KO mice expressed 2-fold less a-SMA than control mice. By
5 days a-SMA expression had return to levels equivalent to
control. Immunohistology of wound tissue sections revealed
that basal a-SMA expression in normal skin did not appear to be
different between wild-type and IL-6KO mice (Figure 2a and b).
Contrary to mRNA expression, 1 day post wounding no
increase in fibroblast a-SMA protein was evident anywhere in
the wound tissue including cellular infiltrate (Figure 2c and d).
Indeed, little if any granulation tissue or a-SMA protein
expression was evident in fibroblasts up to 96 hours post
wounding (not shown). Five days after wounding, increased
a-SMA protein staining was clearly evident in granulation tissue
of C57 wild-type mice (Figure 2e). IL-6KO mice displayed less
overall granulation tissue formation as previously reported
(Gallucci et al., 2001a), yet in the tissue that had formed very
little a-SMA protein was evident (Figure 2f).
Modulation of a-smooth muscle actin mRNA expression in
fibroblast culture
Epidermal keratinocytes as well as Langerhans’ cells and
dermal fibroblasts readily produce IL-6 (Grellner, 2002), and
dermal fibroblasts from IL-6KO mice provide a useful model
for the determination of the effects of IL-6 as intact IL-6R are
expressed making them responsive to the cytokine, but no
bioactive IL-6 is produced making antagonists unnecessary
(Kopf et al., 1994). To further assess the effect of rmIL-6 on
a-SMA expression in fibroblasts, primary dermal fibroblasts
from IL-6KO mice were cultured on tissue culture plates, and
treated with various concentration of rmIL-6 for 2 hours as
described. Total RNA was isolated and a-SMA expression was
determined by real-time quantitative PCR. IL-6 appears to
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Figure 1. Time course of wound a-SMA mRNA in IL-6KO mice – real-time
PCR analysis. IL-6KO or C57BL/6 mice were wounded, and mRNA was
extracted from wound tissue as described. Expression of mRNA was
determined via real-time PCR utilizing an ABI 7000 SDS system (Applied
Biosystems), and accompanying software. Expression differences were
determined relative to 18s rRNA utilizing the Comparative threshold cycle
method. (a) Changes in expression over time, diamonds¼wild-type control,
squares¼ IL-6KO mice. (b) Percent IL-6KO expression of a-SMA relative to
wild-type control, data are expressed as mean7standard deviaton (n¼ 5
animals per data point).
Figure 2. Expression of a-SMA in wound tissue. IL-6KO or C57BL/6 mice
were wounded and wound tissue was collected at various time points after
injury. Formalin-fixed, paraffin-embedded tissue sections of wound tissue
were immunohistologically stained with anti a-SMA (green) and nuclear stain
(dapi, blue). (a and b) Unwounded C57BL/6 and IL-6KO skin, respectively.
(c and d) C57BL/6 and IL-6KO wound infiltrating cells 24 hours post injury.
(e and f) C57BL/6 and IL-6KO wound granulation tissue 5 days post injury.
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have variable effects on a-SMA mRNA expression in cultured
IL-6KO fibroblasts (Figure 3). At 1 ng/ml, rmIL-6 significantly
induced a-SMA mRNA (B2-fold), whereas concentrations of
10 and 50 ng/ml showed a progressive decrease of expression
up to approximately 2-fold below control.
Modulation of a-smooth muscle actin protein expression in
fibroblast culture
To determine whether protein levels of a-SMA were
modulated similarly to mRNA, IL-6KO dermal fibroblasts
were treated with various concentrations of rmIL-6 in low
serum media, and total protein was collected after 0, 24, 48,
and 72 hours incubation. Protein expression of a-SMA
(relative to total actin) was determined by Western blot.
Figure 4 shows a clear induction of a-SMA protein at 1 ng/ml
rmIL-6 after 24 hours. Concentrations of 41 ng/ml did not
significantly increase a-SMA protein compared to control.
Incubations of 424 hours showed marked induction of
a-SMA protein in fibroblast cultures regardless of treatment.
Transcriptional activation of a-SMA expression in vitro
To determine whether a-SMA mRNA increases were trans-
criptionally modulated, dermal fibroblast cultures were
treated with rmIL-6 to induce a-SMA expression, and exposed
to the transcriptional inhibitor Actinomycin-D (Act-D). One
hour after addition of 1 ng/ml rmIL-6, Act-D (50 mg/ml) was
added, and RNA samples were isolated at various time points
after inhibitor treatment. The expression of a-SMA was
upregulated approximately 3-fold at the time of transcrip-
tional inhibition (Figure 5). However, a-SMA mRNA content
decreased significantly 5 minutes post-Act-D addition, and
remained not significantly different from control for the
remainder of the experiment (40 minutes).
IL-6 treatment causes extracellular signal-regulated kinase 1/2
phosphorylation in dermal IL-6KO fibroblasts
The IL-6 receptor can activate both the JAK/signal transducers
and activators of transcription (STAT), and extracellular
signal-regulated kinase (ERK) kinase signal transduction
pathways. To determine which transduction pathways were
induced in dermal IL-6KO fibroblasts, protein samples were
taken from 1 to 20 minutes following treatment with 1 ng/ml
rmIL-6. ERK1/2 phosphorylation was apparent after 1 minute,
while reaching a maximal level 5 minutes post-treatment,
whereas increased phospho-STAT3 when compared to total
STAT3 protein was not increased at any time point (Figure 5).
JAK1 and ERK kinase inhibition decreases a-SMA expression in
cultured IL-6KO fibroblasts
Because ERK1/2 was rapidly activated following IL-6
treatment, and phosphorylation of this kinase is mediated
by JAKs, specific signal transduction inhibitors were utilized
to determine which kinases were necessary for the induc-
tion of a-SMA expression. Dermal fibroblasts from IL-6KO
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Figure 3. IL-6 modulates a-SMA mRNA expression in fibroblast culture.
Primary dermal fibroblasts from IL-6KO mice were grown to 80% confluence
on 100 mm tissue culture plates, and serum/growth factor starved for 4 hours.
Semiconfluent cultures were treated with various concentrations of rmIL-6,
and mRNA was isolated from treated fibroblasts after a 2-hour incubation.
Expression of mRNA was determined via real-time PCR utilizing an ABI 7000
SDS system (Applied Biosystems), and accompanying software. Expression
levels are represented relative to 18s rRNA utilizing the ddCt method. Data are
expressed as mean7standard error (n¼ 5 replicate experiments) percent saline
control. (*significantly different from serum-free media control, Po0.05).
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Figure 4. IL-6 induces a-SMA protein expression in fibroblast culture.
Primary dermal fibroblasts from IL-6KO mice were grown to 80% confluence
on 100 mm tissue culture plates. Growth media was replaced with low serum
(0.1% fetal bovine serum) media and the semi-confluent cultures were treated
with various concentration of rmIL-6 for 24 hours. Total cellular protein was
prepared, and a-SMA expression was determined via Western blot. Lane 1:
0.0 ng/ml rmIL-6, lane 2: 1.0 ng/ml rmIL-6, lane 3: 10 ng/ml rmIL-6, lane 4:
50 ng/ml rmIL-6.
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Figure 5. Act-D does not stabilize IL-6 induced a-smooth muscle actin
mRNA. Primary dermal fibroblasts from IL-6KO mice were grown to 80%
confluence on 100 mm tissue culture plates then incubated with 1 ng/ml rmIL-
6 for 1 h. Act-D (5.0 mg/ml) was added to the cultures and RNA collected from
cells at the indicated time points. Expression of a-SMA was determined by
real-time PCR utilizing an ABI 7000 SDS system (Applied Biosystems), and
accompanying software. Expression levels are expressed relative to 18s rRNA
utilizing the ddCt method. Graphic representation of the image analysis is
shown.
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mice were treated with pan-JAK (JAK inhibitor I, 10 mM),
JAK2 (AG490, 40 mM), JAK3 (WHI-P154, 10 mM), or ERK1/2
(PD98059, 10 mM) inhibitors for 30 minutes before addition
of 1 ng/ml rmIL-6. Two hours post-rmIL-6 treatment a-SMA
mRNA expression was assessed. JAK inhibitor I and PD98059
significantly decreased a-SMA expression (Figure 6a), where-
as inhibitors of JAK2 and 3 showed slight but not significant
inhibition (Figure 6b–d).
Suppressors of cytokine signaling 3 is induced in fibroblast
cultures following IL-6 treatment
IL-6R signaling initiated JAK/STAT signaling is regulated
by a feedback mechanism that involves suppressor of
cytokine signaling 3 (SOCS3) (Heinrich et al., 2003). Figures
2 and 3 show that concentrations of rmIL-6X10 ng/ml do not
significantly induce a-SMA mRNA or protein expression
(respectively). Because it appears as though a-SMA expres-
sion is dependent on JAK activity, rmIL-6-induced SOCS3
expression in IL-6KO fibroblasts was examined. Dermal
fibroblasts from IL-6KO mice showed a dose–response
increase in SOCS3 in response to rmIL-6 treatment, ranging
from a 2-fold increase at 1 ng/ml to a nearly 7-fold increase at
50 ng/ml (Figure 7).
DISCUSSION
IL-6KO mice display greatly impaired wound healing
as evidenced by delayed wound closure, incomplete
re-epithelialization, decreased inflammation, granulation
tissue formation, and neovascularization (Gallucci et al.,
2000; Lin et al., 2003). This impairment was noted for as long
as 15 days, nearly triple the normal healing time. IL-6KO
mice express normal levels of functional IL-6 receptor (Kopf
et al., 1994), and wound healing could be reconstituted by
treating IL-6KO mice with rmIL-6 (Gallucci et al., 2001a; Lin
et al., 2003) or an IL-6 expression plasmid (Gallucci et al.,
2001a). Whereas wound closure is significantly inhibited in
IL-6KO mice, and it has been shown that the expression of
a-SMA, a differentiation marker of the myofibroblast, is
induced in pancreatic fibroblast cultures by IL-6 treatment
(Mews et al., 2002), it is unclear what role IL-6 plays in the
regulation of expression of this contractile protein in the
skin during healing. Herein, we show that IL-6KO mice
display dysregulated a-SMA expression during wounding,
and that rmIL-6 can both induce and inhibit fibroblast a-SMA
expression in vitro.
IL-6 is expressed in wounded skin in two distinct phases. IL-
6 is initially upregulated quickly after skin injury, with robust
protein levels peaking approximately 12 hours post injury,
but drops to near basal levels by 24 hours (Mateo et al., 1994).
The second phase of IL-6 expression in the wound, begins
after approximately 48 hours, where cytokine levels gradually
reach steady state, albeit at a lower tissue concentration than
the initial pulse, from 3–7 days post injury (Mateo et al., 1994).
Despite the fact that there is evidence in the literature that
IL-6 can modulate the expression of a-SMA, the role it plays
in skin appears to be complicated and sometimes conflicting.
Cell culture data presented herein seem to support the notion
that IL-6 upregulates a-SMA mRNA expression quickly,
corresponding with the rapid activation of IL-6R signal
transduction. However, in normal wounds, a-SMA expression
is not apparent in granulation tissue until approximately 5
days post injury (Tomasek et al., 2002). Furthermore, the
expression of a-SMA mRNA following wounding of IL-6KO
mice is initially (B24 hours) greatly increased compared to
control (Figure 1), indicating that IL-6 might play an
inhibitory role in a-SMA expression, and seemingly contra-
dicting our in vitro data. This is further complicated by the
fact that a-SMA mRNA levels do not seem to follow protein
levels in fresh wounds in IL-6KO mice (Figure 2).
The observed discrepancies between in vitro and in vivo
results, as well as mRNA and protein expression are not
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Figure 6. IL-6 treatment activates ERK1/2 but not STAT3 phosphorylation in
dermal fibroblasts. Primary dermal fibroblasts from IL-6KO mice were grown
to 80% confluence on 100 mm tissue culture plates, and treatments were
applied as indicated. Total cellular protein was isolated from the treated
cultures at the indicated time points. Western blot analysis was performed
utilizing 25mg of total protein, and bands were detected with anti-
phosphoprotein antibodies (Cell Signaling Tech., Beverly, MA). Blots were
imaged using a Molecular Imager FX Pro Plus (BioRad, Hercules, CA).
Photographs are representative of three identical experiments.
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Figure 7. Inhibition of JAK and ERK modulation of a-SMA mRNA expression.
Primary dermal fibroblasts from IL-6KO mice were grown to 80% confluence
on 100 mm tissue culture plates. Cultures were treated with specific kinase
inhibitors for (a) pan-JAK (JAK inhibitor I) (b) JAK2 (AG490), (c) JAK3 (WHI-
P154), and (d) ERK (PD98059) for 30 minutes. Semiconfluent cultures were
treated with 1 ng/ml rmIL-6, and mRNA was isolated from treated fibroblasts
after 2 hours. Expression of mRNA was determined via real-time PCR utilizing
an ABI 7000 SDS system (Applied Biosystems), and accompanying software.
Expression differences were determined relative to 18s rRNA utilizing the
ddCt method.
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entirely unexpected as the regulation of a-SMA expression
has been shown to be controlled at multiple levels. For
instance, the expression of a-SMA mRNA is readily detected
in bovine brain microvessels, yet no protein is detected in
capillary endothelial cells or pericytes by immunohistology
(Boado and Pardridge, 1994). In the developing heart tissue
of chicken embryos, a-SMA mRNA is expressed much earlier
than protein (Colas et al., 2000). In fibroblast cultures, the
DNA-binding proteins Pura, Purb, as well as MSY1 (Kelm
et al., 1999), and its mouse homologue YB-1 (Zhang et al.,
2005) are known to activate transcription of a-SMA, yet
also shuttle into the cytosol, bind to its mRNA, and inhibit
translation of the sequence. Thus, unique checkpoints
seem to exist that regulate the expression of a-SMA at both
transcriptional and post-transcriptional levels. One purpose
for multilevel control of this gene may be to inhibit its
inappropriate expression. For instance, increased a-SMA
expression inhibits fibroblast motility (Ronnov-Jessen and
Petersen, 1996), and myofibroblasts themselves inhibit
re-epithelialization (Moulin et al., 2000). Thus, it would
seem necessary for both fibroblast migration and re-epithe-
lialization to proceed before myofibroblast differentiation
for proper healing to occur. Therefore in the early wound,
high levels of expression of IL-6 might activate one of
these ‘‘checkpoints’’, and inhibit early inappropriate a-SMA
expression at the transcriptional level. Indeed, we find that
higher concentrations (41 ng/ml) inhibit a-SMA expression
in vitro (Figure 3). However, it is not known whether the
aforementioned regulatory mechanisms are associated with
IL-6R signaling, and it seems clear that IL-6 is just one of
multiple signals that affect a-SMA expression in fibroblasts, as
a translational block seems to function quite well in IL-6KO
mice in the early phases of healing (Figure 2).
The second phase of IL-6 expression during wound
healing (472 hours) appears to coincide with myofibroblast
formation and wound closure (see Tomasek et al., 2002 for
review). At this point, IL-6 expression is lower than the initial
pulse, yet more persistent (Mateo et al., 1994). Although we
do not show the direct effects of IL-6 on fibroblasts in vivo,
it was found that IL-6KO mice express markedly decreased
a-SMA protein levels in granulation tissue after 5 days
(Figure 2), and low concentrations of IL-6 induce the
expression of a-SMA in IL-6KO fibroblast culture (Figures 3
and 4). Thus, we postulate that perhaps by this stage of
healing, IL-6 might aid in myofibroblast function and wound
closure by promoting fibroblast differentiation as defined
by a-SMA expression. Interestingly, Figure 4 indicates that
fibroblast cultures display increased a-SMA protein expres-
sion that corresponded with age of culture, which was
irrespective of IL-6 treatment beyond 24 hours. Indeed, it is
known that when cultured on tissue culture plastic, fibro-
blasts will spontaneously differentiate toward a myofibro-
blastic phenotype (Tomasek et al., 2002), as a result of
tractional forces encountered and this is especially apparent
in fibroblasts of mouse origin. Thus, it seems that IL-6 is one
of many mediators that can modulate a-SMA expression, and
may augment or work in concert with other factors to induce
differentiation of dermal fibroblasts.
The fact that the modulation of a-SMA expression by IL-6
appears to be concentration dependent, it is not surprising as
IL-6 is well known to be a very (arguably the most)
pleiotropic cytokine, displaying a multitude of activities in
various tissues (Sehgal, 1990). The reasons for this are largely
unknown. A clue to this paradox may lie in the regulation of
IL-6R signal transduction. The IL-6 receptor is composed
of two basic subunits, the function and signal transduction of
which has been extensively reviewed elsewhere (Heinrich
et al., 2003). IL-6 can initiate transduction through the IL-6Rb
(gp130) subunit leading to the rapid activation of numerous
signaling paths including that of JAK/STAT3, and ERK/
mitogen-activated protein kinase (MAPK). Three different
JAK kinases (JAKs 1, 2, and 3) can interact with the IL-6R, to
activate various STATs, and the MAPK pathway can be
activated indirectly through recruitment of SH2 containing
protein tyrosine phosphatase 2. The MAPK pathway can
activate several transcription factors including AP-1, CEBPb,
and NF-kB, as well as Elk-1 which can affect smooth muscle
gene expression through the modulation of serum response
factor activity (Meyyappan et al., 1996; Sobue et al., 1999;
Wang et al., 2004).
The present study demonstrated that the induction of
a-SMA mRNA in IL-6-treated IL-6KO fibroblasts seems to be
at least partially transcriptionally regulated as the transcrip-
tional inhibitor Act-D treatment greatly decreases this genes
mRNA levels (Figure 5). To further investigate the relationship
between IL-6R signaling events and a-SMA gene transcrip-
tion, the JAK/STAT and ERK signaling pathways were assessed
in rmIL-6-treated fibroblasts from IL-6KO mice by Western
blot. It was previously reported that 25 ng/ml rmIL-6 indu-
ced rapid STAT3 activation in cultured IL-6KO fibroblasts,
whereas ERK1/2 was not modulated (Gallucci et al., 2004).
Interestingly, in the present study it was found that 1 ng/ml
rmIL-6 induced only ERK1/2 phosphorylation in cultured
IL-6KO fibroblasts. ERK1/2 required approximately 5 minutes
to reach maximum phosphorylation, whereas STAT3 phos-
phorylation levels remained constant throughout the experi-
ment (Figure 6). Whereas this indicated that primarily the
MAPK pathway was induced, the IL-6R modulates this
pathway through JAK-mediated phosphorylation of SH2
containing protein tyrosine phosphatase 2 as stated earlier.
Thus, it was not clear which JAK enzymes contributed to the
induction of a-SMA expression. To investigate this further,
cultured IL-6KO fibroblasts treated with 1 ng/ml rmIL-6 were
exposed to specific inhibitors for each of the three JAK
kinases, and MAPK. Of the four treatments only the inhibi-
tors JAK-inhibitor I (pan JAK inhibitor) and PD98059 (ERK)
produced a significant decrease in a-SMA mRNA expres-
sion (Figure 7a and d). Inhibitors of JAK2 and 3 did not
significantly decrease a-SMA mRNA expression, indicating
that JAK1 is initially responsible for the induction of this gene.
This is not surprising as JAK1 is activated preferentially by the
IL-6R and responsible for the majority of its signaling activity
(Heinrich et al., 2003). It should be noted that inhibition of
JAK2, and 3 did slightly decrease a-SMA expression (Figure
7b and c), and thus may have minor roles in the modulation
of this gene. However, currently there are no studies that
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directly implicate the JAK/STAT or MAPK pathways in the
induction of a-SMA gene expression.
Similar to induction, the inhibition of a-SMA mRNA
expression in IL-6KO fibroblasts by IL-6 may occur through
several routes, as there are several mechanisms by which
IL-6 signaling can be terminated. There is significant cross-
talk between JAK/STAT and other signaling pathways. For
instance, SMA and MAD related protein 3 transactivation is
necessary for transforming growth factor-b-induced a-SMA
expression (Hu et al., 2003), and transforming growth factor-
bR/SMA and MAD related protein 3 signaling is inhibited
by IFN-g activation of JAK1, through the induction of
the inhibitory transcription factor SMA and MAD related
protein 7 (Ulloa et al., 1999). Similarly, SMA and MAD
related protein 3 and 4 can inhibit IL-6 signaling (Zauberman
et al., 2001). Additionally, it is well known that IL-6 signaling
is regulated by a multicomponent negative feedback loop (for
a review see Heinrich et al., 2003). For instance, the family of
IL-6R signaling inhibitors, known as suppressors of cytokine
signaling (SOCS), inhibit JAK activity, and IL-6R activation
specifically upregulates the expression of SOCS1–3. Indeed,
SOCS3 is induced in rmIL-6-treated IL-6KO fibroblasts in a
dose–response manner (Figure 8). As JAK activation is
necessary for IL-6R-mediated MAPK signal propagation, it
could be that SOCS proteins are responsible for the down-
regulation of a-SMA in cultured IL-6KO fibroblasts at higher
concentrations of IL-6.
When considered with previous articles, the present study
supports the hypothesis that IL-6 assists skin wound healing at
multiple levels most likely by virtue of its highly pleiotropic
nature, and variable expression during skin wound healing.
It may be that robust early wound IL-6 expression promotes
early events such as keratinocyte migration through the
modulation or maintenance of fibroblast phenotype. Where-
as, later lesser upregulation of the cytokine, in combination
with other factors, could assist in wound closure by inducing
the myofibroblast phenotype. Although it does appear that
IL-6 plays a complex role in the modulation of skin a-SMA
expression in vivo and in vitro, the exact mechanism by
which this occurs remains unknown. Clearly, further research
will be necessary to determine the exact the role of IL-6 in
wound closure and healing.
MATERIALS AND METHODS
Reagents
rmIL-6 was purchased from Invitrogen (Carlsbad, CA). The signal
transduction inhibitors, AG490 (JAK2), JAK inhibitor I (pan-JAK),
WHI-P154 (JAK3), and PD98059 (ERK1/2) were purchased from
EMD Biosciences (San Diego, CA).
In vivo wounding
Experimental animals were treated in accordance with the criteria
outlined in the PHS Policy on Humane Care and Use of Laboratory
Animals, and the ‘‘Guide for the Care and Use of Laboratory
Animals’’ (NIH publication 86–23), in facilities accredited by
Association for Assessment and Accrediation of Laboratory Animal
Care. IL-6-deficient (C57BL/6J-IL6tmKopf) or wild-type (C57BL/6J)
mice were wounded as previously described (Gallucci et al., 2001a).
Briefly, male wild-type mice or IL6KO mice (Jackson Laboratories,
Bar Harbor, ME) weighing 22–28 g and approximately 8–12 weeks
old were housed in polycarbonate cages containing hardwood chip
bedding at room temperature (21721C) on a 12-hour light/dark
cycle. Mice were anesthetized by intraperitoneal injection with
80 mg/kg pentobarbital, and the left flank was clipped and swabbed
with Betadine (Purdue Fredrick Co., Norwalk, CT) and 70% ethanol
three times before wounding. Four millimeter punch biopsies were
performed on the shaved area. After various healing periods, wound
tissue was collected (2–3 mm border was excised around the wound)
and preserved by flash freezing in liquid nitrogen.
Dermal fibroblast isolation and culture
The dermis was collected and separated from the epidermis as
described previously (Gallucci et al., 2004). Briefly, newborn IL-
6KO mouse pups (0–48 hours old) were killed by decapitation, rinsed
in 70% ethanol, and the skin was removed. Excised mouse skin was
placed in culture dishes dermis side down, in Hank’s balanced salt
solutionþ 3.6% dispase (Sigma, St. Louis, MO) and incubated at 41C
overnight. The dermis was separated from the epidermis, placed
in Hank’s balanced salt solutionþ 0.05% Type 1 collagenase and
incubated at 371C for 30 minutes with constant agitation. The cell
suspension was filtered through sterile gauze into a 50 ml conical
tube. An equal volume of DMEMþ 5% fetal bovine serum contain-
ing 60 IU/ml penicillin, 100 IU/ml streptomycin, and 4 mM glutamine
(DMEMþ 5%) was added and centrifuged at 200 g for 10 minutes.
Fibroblasts were resuspended in DMEMþ 5%, plated at 8 103/cm2
in 150 mm culture dishes, and incubated at 371C and 5% CO2 and
95% room air. The primary IL-6KO fibroblasts were passaged once
and utilized for subsequent experiments. Dermal cells were cultured
in DMEM which does not support keratinocyte growth, and the cells
were passaged once to minimize contamination from these cells, but
not passaged further as cultures begin to take on a proto-
myofibroblast (Tomasek et al., 2002) appearance and greatly
increase a-SMA expression (unpublished observations). Cells were
phenotyped by gross morphology, and possessed the classical long
spindle shape of fibroblasts.
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Figure 8. IL-6 induces SOCS3 mRNA expression in fibroblast culture.
Primary dermal fibroblasts from IL-6KO mice were grown to 80% confluence
on 100 mm tissue culture plates, and serum/growth factor starved for 4 hours.
Semiconfluent cultures were treated with various concentration of rmIL-6,
and mRNA was isolated from treated fibroblasts after a 2-hour incubation.
Expression of mRNA was determined via real-time PCR utilizing an ABI 7000
SDS system (Applied Biosystems), and accompanying software. Expression
levels are expressed relative to 18s rRNA utilizing the ddCt method. Data are
expressed as mean7standard deviaton (n¼ 5) percent saline control
(*significantly different from serum free media control, Po0.05).
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Real-time quantitative PCR
Primary dermal fibroblasts from IL-6KO mice were grown to 80%
confluence on 100 mm tissue culture plates, and serum/growth
factor starved for 4 hours. Semiconfluent cultures were treated with
various concentrations of rmIL-6, and mRNA was isolated from
treated IL-6KO fibroblasts after a 2-hours incubation. The IL-6R
signal transduction pathway is very rapidly activated following IL-6
binding, resulting in mRNA induction within seconds to minutes
(Heinrich et al., 2003). Shorter (1–2 hours) time points, as were
chosen for the present study, allow for sufficient accumulation of
mRNA, yet indicate a more direct modulation as a result of IL-6
treatment as the influence of de novo protein synthesis is minimal.
Total RNA from mouse skin or dermal IL-6KO fibroblasts was
prepared and cDNA synthesized as described previously (Gallucci
et al., 2004). Primers and probes for mouse a-SMA, SOCS3, and 18s
rRNA were acquired from Applied Biosystems (Assays-on-demand,
Foster City, CA). Quantitative PCR was performed on an ABI PRISM
7000 SDS according to the manufacturer’s instructions. Quantitative
values of genes of interest are normalized based on 18s rRNA
content.
Immunohistology
Anti-a-SMA and Alexa 488 anti-mouse antibodies were obtained
from Sigma (St Louis, MO). Formalin-fixed paraffin-embedded
sections were dewaxed, permeabilized in 0.1% NP40, and stained
for a-SMA essentially as previously described (Tomasek et al., 2005).
Slides were washed, coverslipped, and staining was visualized by
fluorescent microscopy.
Western blot analysis
IL-6KO fibroblasts were prepared as described above, and cultured
to 90% confluency in 150 cm2 culture plates. Before treatment,
fibroblast cultures were washed twice with phosphate-buffered
saline, and culture media was replaced with low serum (0.1% fetal
bovine serum) DMEM containing, 60 IU/ml penicillin, 100 IU/ml
streptomycin, and 4 mM glutamine. Low serum medium was
necessary to maintain viability of primary fibroblasts overnight.
Following a 4-h incubation in low serum medium, treatments were
applied to the cultures in fresh low serum DMEM. At indicated time
points, culture plates were rinsed once with ice-cold phosphate-
buffered saline, and total cell protein was collected in 150 ml of
2 Laemmli denaturing sample buffer (Sigma #S3401). Approxi-
mately 25 mg of total protein was electrophoresed on 10%
SDS-PAGE (10 cm 10 cm) minigels (Gradipore, Frenchs Forest,
AUS) at 90 V for 45 minutes, and electrophoretically transferred
onto nitrocellulose sheets (Pierce, Rockford, IL) at 25 V for 2.5 hours.
Following transfer, the blots were blocked in Tris-buffered saline
containing 1% cold-water fish gelatin (Sigma, St Louis, MO), and
50 mM NaF for 1 hour at room temperature. Monoclonal anti-a-SMA,
rabbit anti-actin (Sigma), or anti-p-STAT3/total STAT3, p-ERK1/2/
total ERK1/2 (Cell Signaling, Beverly, MA) were applied to the blots
at a 1:1000 dilution in Tris-buffered saline containing 1% fish
gelatin, 0.1% Tween 20, and 50 mM NaF overnight at 41C. The blots
were washed 3 in Tris-buffered saline containing 0.1% Tween 20,
and exposed to a fluorescently labeled secondary anti-species
polyclonal antibody(s) (Rockland, Gilbertsville, PA) at a 1:30,000
dilution in Tris-buffered saline containing 1% fish gelatin and 0.1%
Tween 20 for 1 hour. Following three washes in Tris-buffered
salineþ 0.1% Tween, the blots were imaged via the Molecular
Imager ProPlus imaging system (BioRad, Hercules, CA).
Statistical analysis
All experiments were replicated and representative findings are
shown. Statistical significance was determined by one-way ana-
lysis of variance. When the F-value was significant, the means
were compared using Fisher’s post hoc analysis. In all statistical
comparisons, a P-value of o0.05 was used to indicate a significant
difference.
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